Cephalon Myotrophin
Executive Summary
FDA Peripheral & CNS Drugs Advisory Committee will revisit Chiron/Cephalon's NDA for Myotrophin (mecasermin) for treatment of amyotrophic lateral sclerosis April 9. The committee has considered the drug twice before, once at the Treatment IND stage and once at the NDA stage, and both times said that another study would be required to support approval. Cephalon has refused to invest more in the project prior to approval. The meeting will take place at the Bethesda, Md. Holiday Inn beginning at 8:30 a.m...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth